The new wave of immunotherapy cancer medicines
The untapped potential for Australians
Immunotherapies represent the new wave in cancer medicines. Deloitte Access Economics has developed this point-in-time review for the community to describe the shift to a new wave of cancer medicines and the potential they are showing in the fight against cancer.
As the leading cause of disease burden for patients, families and the health system, cancer is a significant public health issue in Australia. An estimated 134,174 new cancer cases will be diagnosed in 2017, while 47,753 people are estimated to die due to cancer in the same year.
The advent of immunotherapies signals the onset of a new paradigm in cancer treatment. With innovations and new applications revealing themselves at unprecedented speed, it is harder than ever for health systems, clinicians, patients and the public to keep pace.
Deloitte Access Economics has developed this point-in-time review for the community to describe the shift to a new wave of cancer medicines and the potential they are showing in the fight against cancer.
This review explores the rise of immunotherapies in cancer treatment and the huge potential these medicines are showing in the fight against cancer. The research provides an account of the patient experience within this new treatment environment, including specific barriers to awareness about and access to the new therapies. The overarching objective is to catalyse a public discussion of what immunotherapies mean to Australia, and how we now respond to the rising wave of immunotherapies visible on the cancer treatment landscape.
Published: October 2017